BAR502 / BAR Pharmaceuticals - LARVOL DELTA

BAR-502-001: To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: BAR Pharmaceuticals s.r.l. | Trial completion date: Sep 2025 ➔ Jul 2026 | Trial primary completion date: Aug 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Metabolic Dysfunction-Associated Steatohepatitis

BAR-502-001: To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: BAR Pharmaceuticals s.r.l. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis